1140 GMT - Argenx's positive results for a midstage clinical trial in celiac disease vindicates its CEO change earlier this year, Bernstein analysts say in a research note. The Amsterdam-based biotech company said a drug candidate it acquired through its Forte Biosciences deal, FB102, hit the goal in a study, reinforcing the potential of a medicine being tested for two diseases with little or no existing nonsystemic drug treatment options, the analysts say. "A key rationale for the CEO transition was to diversify the organic pipeline with external innovation," the analysts add. Argenx separately said it would discontinue a trial for its main drug Vyvgart in Sjogren's disease. This should come as little surprise given that Sjogren's is a heterogeneous disease that has become a research-and-development "graveyard" for the industry, according to Bernstein. Shares fall 16%.